Drug intelligence / Profile preview

BP-C1 + BP-C2

Development stage: Unknown
Lead developer: Meabco
Modality: Small Molecules
Administration: Intramuscular

Overview

BP-C1 + BP-C2 is a combination therapy developed by Meabco A/S, consisting of a platinum-based anticancer agent (BP-C1) and a non-platinum benzene-poly-carboxylic acid complex (BP-C2). BP-C1 is a coordination complex of cis-diammineplatinum(II) with benzene-poly-carboxylic acids (BPCAs), designed to deliver platinum to tumor cells with lower systemic toxicity compared to traditional platinum agents like cisplatin. BP-C2 is a BPCA-based formulation without platinum, intended to act as an immunomodulator and cytoprotective agent to enhance the efficacy and tolerability of the treatment. The combination has been investigated in clinical trials for metastatic breast cancer and pancreatic cancer, particularly in patients who have failed standard therapies.

Other names: BP-C1 + BP-C2

Targets

DNA

Beyond the preview

Go deeper on BP-C1 + BP-C2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BP-C1 + BP-C2.

Explore the full profile